Skip to main content

Advertisement

Table 4 Trend estimates for incidence, prevalence, and mortality with respect to treatment with anti-diabetic agents

From: Counting drugs to understand the disease: The case of measuring the diabetes epidemic

Run-in Treatment Gender Prevalence Incidence Mortality among treated Relative Mortality
One year All anti-diabetic F 1.036 1.032, 1.040 1.045 1.035, 1.055 0.973 0.959, 0.987 0.991 0.986, 0.995
   M 1.044 1.040, 1.048 1.045 1.036, 1.054 0.974 0.961, 0.987 0.977 0.973, 0.982
  Insulin F 1.036 1.030, 1.043 1.048 1.033, 1.064 0.977 0.955, 1.000 0.990 0.986, 0.994
   M 1.045 1.039, 1.050 1.067 1.053, 1.082 1.000 0.976, 1.023 0.977 0.973, 0.981
  Oral antidiab. F 1.045 1.039, 1.051 1.052 1.042, 1.059 0.969 0.953, 0.986 0.992 0.987, 0.996
   M 1.052 1.046, 1.058 1.049 1.040, 1.058 0.959 0.943, 0.974 0.979 0.975, 0.984
Two year All anti-diabetic F 1.035 1.031, 1.039 1.048 1.038, 1.058 0.972 0.959, 0.986 0.990 0.986, 0.995
   M 1.045 1.040, 1.049 1.045 1.035, 1.054 0.978 0.965, 0.991 0.978 0.974, 0.982
  Insulin F 1.034 1.028, 1.040 1.049 1.033, 1.065 0.970 0.949, 0.992 0.990 0.986, 0.994
   M 1.045 1.040, 1.051 1.065 1.050, 1.080 1.005 0.983, 1.028 0.977 0.973, 0.982
  Oral antidiab. F 1.043 1.037, 1.049 1.055 1.045, 1.066 0.970 0.954, 0.987 0.991 0.987, 0.995
   M 1.052 1.046, 1.058 1.050 1.040, 1.060 0.964 0.949, 0.979 0.980 0.976, 0.984
Variable All anti-diabetic F 1.046 1.042, 1.050 1.032 1.023, 1.041 0.974 0.962, 0.985 0.991 0.987, 0.995
   M 1.053 1.049, 1.057 1.028 1.020, 1.036 0.973 0.962, 0.984 0.979 0.975, 0.982
  1. Estimated age-adjusted, annual trends with 95%-confidence intervals for different categories of anti-diabetic drugs and with different lengths of run-in periods, Fyn County, Denmark, 1992–2003. For prevalence the trend estimate is given as an odds-ratio based on logistic regression, whereas the remaining estimates are rate-ratios based on Poisson regression. The start of the study period depends on the length of run-in period used.